Company news
Hoth Therapeutics, Inc. news in 2019
Hoth Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.
Hoth Therapeutics, Inc. Issues 2019 Shareholder Letter
December 22, 2019
Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board
December 16, 2019
Hoth Therapeutics And North Carolina State University Initiate Preclinical Gene Therapy Study For The Treatment Of Asthma
December 8, 2019
Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy
November 25, 2019
Hoth Therapeutics Initiates Preclinical Study Including Topical Form of Aprepitant for Dermatological Treatment Relating to Side Effects of Cancer Medication
November 13, 2019
Hoth Therapeutics Initiates Confirmatory Study for Lupus Treatment
November 5, 2019
Hoth Therapeutics Successfully Completes Phase I of In-Life Dose Escalation Study for Treating Eczema
October 7, 2019
Hoth Therapeutics and Zylö Therapeutics Finalize Agreement
August 20, 2019
Hoth Therapeutics, Inc. Announces Positive Results from Pilot Study of BioLexa on Diabetic Skin Ulcers
July 21, 2019
Hoth Therapeutics, Inc. Expands Working Relationship with the George Washington University and Enters Exclusive License Option Agreement
July 14, 2019
Hoth Therapeutics, Inc. Enters into Sponsored Research Agreement with the George Washington University
June 26, 2019
Hoth Therapeutics to Begin Production of BioLexa Therapeutic for Upcoming Toxicology and Clinical Trials
June 9, 2019
Hoth Therapeutics Forms Wholly Owned Australian Subsidiary, in Preparation of Upcoming Clinical Trials for Atopic Dermatitis Solution
June 5, 2019
Decks in 2019
- Investor Presentation (October 2019)
Investor deck · 33 slides · October 2019